BeOne Medicines Ltd. (BeOne) reported that a wholly-owned Chinese subsidiary has reached an agreement with the local tax authority to revise previously filed returns, leading to an income-tax payment—inclusive of late-payment surcharges—of approximately RMB446.00 million.

The company confirmed: • Timing: The payment will be settled promptly, with no administrative penalty attached. • Accounting treatment: The entire RMB446.00 million will be recorded as income-tax expense in BeOne’s fiscal-year 2026 financial statements. • Impact: Management stated the adjustment does not constitute a prior-period accounting error; therefore, no retrospective restatement of historical financials is required. The ultimate effect on FY2026 net income will be determined upon completion of the audited results for the year ending 31 December 2026. • Outlook: BeOne does not expect the tax settlement to have a material adverse impact on its financial condition, long-term operating capabilities, or routine business activities.

The announcement was authorized by Chairman John V. Oyler and released in Hong Kong on 26 June 2026.